Latest Articles
Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer - OncLive
Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer OncLive
Published: May 28, 2025, 2:28 p.m.
Bariatric Surgery, Lifestyle Interventions May Cut Endometrial Cancer Risk by 44 Percent: Study Finds - Medical Dialogues
Bariatric Surgery, Lifestyle Interventions May Cut Endometrial Cancer Risk by 44 Percent: Study Finds Medical Dialogues
Published: May 26, 2025, 3:15 p.m.
Ultrasonic prediction model using three-dimensional power doppler for endometrial cancer detection in women with postmenopausal bleeding - Nature
Ultrasonic prediction model using three-dimensional power doppler for endometrial cancer detection in women with postmenopausal bleeding Nature
Published: May 26, 2025, 7:04 a.m.
‘Important step forward’ in endometrial cancer treatment - Medical Republic
‘Important step forward’ in endometrial cancer treatment Medical Republic
Published: May 26, 2025, 4:46 a.m.
Advanced Age as a Predictor of Unsuccessful Bilateral Sentinel Lymph Node Detection Using Radiocolloid Mapping in Patients With Endometrial Cancer: A Prospective Observational Study - Cureus
Advanced Age as a Predictor of Unsuccessful Bilateral Sentinel Lymph Node Detection Using Radiocolloid Mapping in Patients With Endometrial Cancer: A Prospective Observational Study Cureus
Published: May 24, 2025, 12:37 a.m.
Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer - OncLive
Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer OncLive
Published: May 23, 2025, 7:05 p.m.
Endometrial cancer data on Genmab’s Elahere rival beat forecast, fuelling push into phase 3 - Fierce Biotech
Endometrial cancer data on Genmab’s Elahere rival beat forecast, fuelling push into phase 3 Fierce Biotech
Published: May 23, 2025, 1:22 p.m.
Endometrial cancer data on Genmab’s Elahere rival beat forecast, fueling push into phase 3 - Fierce Biotech
Endometrial cancer data on Genmab’s Elahere rival beat forecast, fueling push into phase 3 Fierce Biotech
Published: May 23, 2025, 1:22 p.m.
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment - TipRanks
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment TipRanks
Published: May 23, 2025, 10:59 a.m.
Breakthrough Cancer Data: Genmab Reveals First Rina-S Results for Deadly Endometrial Cancer at ASCO 2025 - Stock Titan
Breakthrough Cancer Data: Genmab Reveals First Rina-S Results for Deadly Endometrial Cancer at ASCO 2025 Stock Titan
Published: May 22, 2025, 9:05 p.m.
Link copied to clipboard!